SAB Biotherapeutics, Inc. (SABS) Balance Sheet

The step-up in equity from $12.0M in 2025Q2 to $214.8M in 2026Q2 appears entirely attributable to contributed capital, since retained losses deepened by roughly $42M across the same period, which suggests the balance sheet has been repaired on the back of investor funding rather than operating performance. Investors should note that the prior decade-plus of cumulative losses remains fully embedded in equity, so the headline expansion does not yet signal a self-sustaining trajectory. The pattern of sharp asset swings — falling to $30.1M then quadrupling to $172.8M within two quarters — implies the company's capitalization is event-driven and may remain episodic.

A current ratio of 9.22 against total liabilities of $23.4M mathematically implies current assets near $216M, meaning roughly $200M of short-term assets sit outside the cash line, and the quality and convertibility of that buffer warrants further investigation before treating liquidity as robust. Given the reported acceleration in operating and free cash outflows, the pace at which cash itself has been drawn down — from $29.4M in 2025Q3 to $8.3M — may indicate that underlying burn is outrunning the replenishment provided by periodic raises. The divergence between a stable current ratio and a halving cash balance suggests investors should monitor cash specifically rather than relying on the aggregate working capital metric.

Debt has drifted lower from $6.8M in 2025Q1 to $5.1M while equity expanded more than tenfold, which implies leverage reduction is a function of dilution rather than debt paydown, and refinancing risk appears immaterial on current terms. The absence of meaningful leverage is consistent with a pre-revenue biotech that has relied on equity issuance, so the constraint on cash flow durability is not debt service but the recurring need to fund operations externally. Should burn persist at the levels observed in 2026, the low D/E ratio suggests borrowing could be an available, though likely expensive, complement to further equity raises.

The swing in retained earnings from -$94.0M in 2025Q3 to -$139.5M in 2025Q2 and back illustrates how the 2025Q3 non-operating gain temporarily flattered accumulated losses before reversing, so the underlying equity base is eroding at a pace closer to the operating deficit than headline retained earnings may suggest. Since essentially no capital has been returned to shareholders and buybacks totaled only $9K, the equity story is one of continuous accumulation through issuance, which may indicate that per-share value is being sustained by new money rather than earnings power. Analysts should treat the reported stock-based compensation as a recurring, if non-cash, claim on future equity value that compounds alongside each new raise.